SCHEMBL2134036

SCHEMBL2134036

CC(C)(C)OC(=O)N(NC(=O)c1ccc(S(N)(=O)=O)cc1)c1ccc(-c2cccs2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 9/20 0.46
CA9 Q16790 6/20 0.46
CA1 P00915 6/20 0.46
CA12 O43570 4/20 0.46
CA14 Q9ULX7 3/20 0.46
GPR119 Q8TDV5 2/20 0.40
HDAC1 Q13547 6/20 0.40
HDAC3 O15379 2/20 0.39
HDAC4 P56524 2/20 0.39
HDAC7 Q8WUI4 2/20 0.39
HDAC2 Q92769 2/20 0.39
HDAC10 Q969S8 2/20 0.39
HDAC11 Q96DB2 2/20 0.39
HDAC8 Q9BY41 2/20 0.39
HDAC6 Q9UBN7 2/20 0.39
HDAC9 Q9UKV0 2/20 0.39
HDAC5 Q9UQL6 2/20 0.39
STAT3 P40763 1/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650775 0.88 HDAC1 (0.44) GPR119HDAC1HDAC3HDAC4HDAC7
SCHEMBL2687336 0.84 HDAC1 (0.41) GPR119HDAC1HDAC2
SCHEMBL2685210 0.84 GPR119 (0.43) GPR119HDAC1HDAC3HDAC4HDAC7
SCHEMBL4618383 0.82 GPR119 (0.40) GPR119HDAC1HDAC3HDAC4HDAC7
SCHEMBL1067203 0.80 ABL1 (0.50) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL2134029 0.75 HDAC1 (0.52) HDAC1HDAC3HDAC4HDAC7HDAC2
SCHEMBL449992 0.74 DRD4 (0.36) GPR119HDAC1HDAC2HDAC6MEN1
SCHEMBL196445 0.73 HDAC1 (0.46) GPR119HDAC1HDAC3HDAC2
Ammonia Solution, Strong SCHEMBL21835780 0.72 HDAC1 (0.45) GPR119HDAC1HDAC3HDAC2
SCHEMBL2137854 0.72 GSK3B (0.43) HDAC1HDAC3HDAC2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120101147-A1 INHIBITION OF HDAC2 TO PROMOTE MEMORY THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) 2012-04-26 US disclosed
CN-102271763-A Inhibition of hdac2 to promote memory 2011-12-07 CN disclosed
EP-2367599-A1 INHIBITION OF HDAC2 TO PROMOTE MEMORY Massachusetts Institute of Technology (US) 2011-09-28 EP disclosed
WO-2010065117-A1 INHIBITION OF HDAC2 TO PROMOTE MEMORY MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101147-A1 INHIBITION OF HDAC2 TO PROMOTE MEMORY HDAC2, HDAC1, HDAC3 CA2 998/4885CA9 3784/4885CA1 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.